Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXERVATE vs INCRELEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OXERVATE (becaplermin) is a recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes wound healing by stimulating chemotaxis and mitogenesis of fibroblasts, smooth muscle cells, and other cells involved in tissue repair.
Insulin-like growth factor 1 receptor agonist; promotes linear growth by stimulating chondrocyte proliferation at epiphyseal plates and exerts anabolic effects on muscle, bone, and other tissues.
Treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have adequate blood supply,Off-label: Treatment of pressure ulcers, venous stasis ulcers
Treatment of growth failure in children with severe primary IGF-1 deficiency (primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH
1 drop in the affected eye(s) twice daily, approximately 6 hours apart.
Intravenous bolus of 0.1 mg/kg given over 1 minute, followed by continuous intravenous infusion of 0.6 mg/kg/min for 30 minutes. Alternatively, a single intravenous bolus dose of 0.3 mg/kg.
Terminal elimination half-life of Cenegermin is approximately 12 hours following topical ocular administration, supporting once-daily dosing
Terminal elimination half-life is approximately 8-10 hours in adults; clinically, steady-state is achieved within 2-3 days.
Becaplermin is a protein that is expected to be degraded into small peptides and amino acids via general protein catabolism; specific hepatic metabolism is not a significant pathway.
Primarily metabolized by proteolysis into smaller peptides and amino acids; not significantly metabolized by CYP enzymes.
Primarily renal elimination of the active metabolite (Cenegermin) as small peptides and amino acids; unchanged drug excretion is negligible
Renal: ~95% of absorbed dose as unchanged drug and metabolites; fecal: <5%.
Cenegermin binding to plasma proteins is minimal (<10%) due to its small protein nature
Approximately 90% bound to insulin-like growth factor binding proteins (IGFBPs).
Vd not determined for topical ocular route; systemic exposure is low, with Vd estimated less than 0.1 L/kg based on limited systemic absorption
Vd ~0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
Topical ocular: Systemic bioavailability is negligible (<1%) due to low corneal penetration and extensive proteolysis at the ocular surface
Subcutaneous: 80-100% (high bioavailability).
No dose adjustment required for renal impairment.
No specific dose adjustment recommended for renal impairment; use with caution in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²) due to limited data.
No dose adjustment required for hepatic impairment.
No specific dose adjustment recommended for hepatic impairment; use with caution in patients with Child-Pugh class C cirrhosis due to potential risk of hypoglycemia.
Safety and efficacy in pediatric patients have not been established.
Not approved for use in pediatric patients. Safety and efficacy in children have not been established.
No specific dose adjustment required; use same dosing as adults.
No specific dose adjustment recommended; elderly patients may be more sensitive to hypoglycemic effects; monitor blood glucose closely.
OXERVATE has been associated with an increased risk of mortality from secondary malignancies in patients who have had a malignant neoplasm. The drug should not be used in patients with active malignancy.
Increased risk of neoplasms; do not use in patients with active or suspected malignancy. Monitor for progression of pre-existing nevi.
Increased risk of malignancy in patients with a history of malignancy; application to ulcers with malignant cells may promote tumor growth; use only on clean, non-infected ulcers; monitor for signs of infection; avoid application to wounds with exposed bone, tendon, or joint capsule.
Risk of malignancy (including intracranial tumors),Lymphoproliferative disorders,Intracranial hypertension (pseudotumor cerebri),Slipped capital femoral epiphysis,Progression of scoliosis,Pancreatitis,Hypoglycemia (especially with fasting or missed meals),Fluid retention (edema, pericardial effusion),Hypersensitivity reactions including anaphylaxis,Thymic hypertrophy
Known hypersensitivity to becaplermin or any product component; active neoplasm at the application site; patients with a history of malignancy (relative contraindication based on black box warning).
Active or suspected malignancy (including intracranial tumors),Closed epiphyses (skeletal maturity),Acute critical illness (due to increased mortality with ICU use),Hypersensitivity to mecasermin or any component
None known; no significant food interactions reported.
Must be administered within 20 minutes of a meal or snack containing carbohydrates to reduce risk of hypoglycemia. Avoid fasting or skipping meals. Grapefruit/grapefruit juice may alter CYP3A4 metabolism; avoid concurrent use. Alcohol can increase hypoglycemia risk; limit or avoid.
OXERVATE contains cenegermin, a recombinant human nerve growth factor. No adequate and well-controlled studies in pregnant women. Animal reproductive studies have not been conducted. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: unknown risk; second and third trimesters: unknown risk.
INCRELEX (mecasermin) is an IGF-1 analog. In animal studies, there is no evidence of teratogenicity; however, data in pregnant women are insufficient. First trimester: No known malformation risk. Second/third trimesters: Fetal overgrowth (macrosomia) may occur if maternal IGF-1 levels are elevated. Caution advised.
No data on presence in human milk, effects on breastfed infant, or milk production. Caution advised; M/P ratio unknown.
Excretion into human milk unknown; molecular weight (7.5 k Da) suggests minimal transfer. M/P ratio not established. Caution recommended; alternative feeding may be considered until more data available.
No pharmacokinetic studies in pregnancy; dose adjustments not established. Use standard dosing with caution.
No established dose adjustments. Physiologic changes in pregnancy (increased renal clearance, plasma volume) may reduce drug levels; however, safety and efficacy data are lacking. Use only if clearly needed with careful monitoring.
OXERVATE (cenegermin-bkbj) is a recombinant human nerve growth factor for neurotrophic keratitis. Administer as one drop in the affected eye(s) six times daily at 2-hour intervals for 8 weeks. Refrigerate at 2-8°C; do not freeze. Protect from light. Discard unused drops after 1 week of first opening. Monitor for corneal epithelial defect closure. Use with caution in patients with active ocular infections or inflammation.
INCRELEX (mecasermin) is recombinant human insulin-like growth factor-1 (IGF-1) used for growth failure in severe primary IGF-1 deficiency. Monitor blood glucose closely due to risk of hypoglycemia; administer within 20 minutes of a meal or snack. Do not use in patients with closed epiphyses, active malignancy, or history of malignancy. Can cause intracranial hypertension (pseudotumor cerebri); monitor for headache, visual disturbances. Injection site reactions common.
Wash hands before each use.,Instill one drop in the affected eye(s) every 2 hours, 6 times daily.,Refrigerate the medication at all times; do not freeze.,Use within 1 week after opening the vial.,Avoid touching the dropper tip to any surface.,Do not use contact lenses during treatment.,Report any eye pain, redness, or vision changes immediately.,Complete the full 8-week course even if symptoms improve.
Do not use INCRELEX if you have cancer or a history of cancer.,Take exactly as prescribed; inject within 20 minutes after a meal or snack to prevent low blood sugar.,Do not inject into the same site repeatedly; rotate injection sites.,Watch for signs of low blood sugar (shakiness, sweating, confusion) and have fast-acting sugar (e.g., juice, glucose tablets) available.,Report severe headache, vision changes, or nausea immediately (possible increased pressure in the skull).,Inform all healthcare providers you are using this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXERVATE vs INCRELEX, answered by our medical review team.
OXERVATE is a Growth Factor (Ophthalmic) that works by OXERVATE (becaplermin) is a recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes wound healing by stimulating chemotaxis and mitogenesis of fibroblasts, smooth muscle cells, and other cells involved in tissue repair.. INCRELEX is a Growth Factor that works by Insulin-like growth factor 1 receptor agonist; promotes linear growth by stimulating chondrocyte proliferation at epiphyseal plates and exerts anabolic effects on muscle, bone, and other tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXERVATE and INCRELEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXERVATE is: 1 drop in the affected eye(s) twice daily, approximately 6 hours apart.. The standard adult dose of INCRELEX is: Intravenous bolus of 0.1 mg/kg given over 1 minute, followed by continuous intravenous infusion of 0.6 mg/kg/min for 30 minutes. Alternatively, a single intravenous bolus dose of 0.3 mg/kg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXERVATE and INCRELEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXERVATE is classified as Category C. OXERVATE contains cenegermin, a recombinant human nerve growth factor. No adequate and well-controlled studies in pregnant women. Animal reproductive studies have not been conducte. INCRELEX is classified as Category C. INCRELEX (mecasermin) is an IGF-1 analog. In animal studies, there is no evidence of teratogenicity; however, data in pregnant women are insufficient. First trimester: No known mal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.